Life Sciences Tools & Services · NYSE

RVTYRevvity, Inc.

Last close
$154.39 -1.7%
52-week range
$81.22 to $171.74
Market cap
$17.2B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$2.86B
+4% vs FY24
Net income
$241M
-11% vs FY24
Free cash flow
$509M
-6% vs FY24
Net cash
-$2.30B
Cash $920M, debt $3.22B

Stock price

+188% since Dec 2016

Valuation vs its own 10 years

Above its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2017, measured at every quarter end. The thin tick is the median.

P/E, trailing
68.3x
13.6x86.9x
92nd percentile, above its median of 34.5x
Price / sales
5.9x
2.7x6.1x
98th percentile, above its median of 4.3x
EV / EBITDA
24.6x
10.1x27.2x
92nd percentile, above its median of 19.3x
Price / free cash flow
29.2x
11.7x1,360x
62nd percentile, above its median of 25.4x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-10-04. Every figure carries its unit.

Valuation

P/E
68.3x
Earnings yield
1.5%
Price / sales
5.9x
Price / book
2.4x
Price / operating cash flow
26.3x
EV / EBITDA
24.6x
EV / sales
6.6x
Free cash flow yield
3.4%

Profitability

Gross margin
n/aNot reported
Operating margin
12.6%
Net margin
8.6%
Return on equity
3.5%
Return on capital
3.4%

Growth per year

Revenue, 3 years
-4.8%
Revenue, 5 years
+1.4%
Revenue, 9 years
+3.4%
EPS, 3 years
-22.8%

Balance sheet

Cash and investments
$593M
Total debt
$2.63B
Net cash
-$2.04B
Debt / equity
0.36x
Current ratio
2.65x

Shares and dividend

Shares outstanding
112M
Share count, 5 years
+4.0%
Beta, 1 year
1.15
Dividend yield
0.2%
Dividend per share, TTM
$0.28
Payout ratio
12.4%

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $729M
RevenueNet income
Gross profitLatest quarter $419M
EBITDALatest quarter $198M
Margins57 / 13 / 9%
GrossOperatingNet
Earnings per shareLatest quarter $0.56
Cash flowLatest quarter $167M
OperatingCapexFree
Cash vs debtLatest quarter $593M
Cash and investmentsTotal debt
P/E historyNow 68.3x
P/E, median 34.5x dashed
P/S historyNow 5.9x
P/S, median 4.3x dashed

Where the revenue comes from

Services went from 20% to 16% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

ProductServices
FY22
80%20%
$3.31B
FY23
88%12%
$2.75B
FY24
85%15%
$2.76B
FY25
84%16%
$2.86B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Product$2.39B83.7%+2%
Services$466M16.3%+12%

Life Sciences Tools & Services peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
TMO Thermo Fisher Scientific Inc. $259B +8% 17.9%36.9x5.5x 88th percentile
A Agilent Technologies, Inc. $49.0B +9% 22.2%34.2x6.7x 64th percentile
WAT Waters Corp $45.2B +81% 4.7%198x8.1x 90th percentile
IQV Iqvia Holdings Inc. $43.7B +9% 12.8%32.2x2.5x 38th percentile
MTD Mettler Toledo International Inc/ $34.6B +7% n/a37.7x8.2x 58th percentile
RVTY Revvity, Inc. $17.2B +5% 12.7%68.3x5.9x 92nd percentile

The company

Sector
Health Care
Industry
Life Sciences Tools & Services
Founded
1937
Headquarters
Waltham, MA
Fiscal year ends
Late December
Website
perkinelmer.com

What it does

PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics. Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about RVTY.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 286 active funds. Crowd level: quiet.

Open the Smart money tab